Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG‐PET scan before transplantation
暂无分享,去创建一个
K. Ohtomo | T. Momose | S. Kako | Y. Kanda | M. Kurokawa | K. Izutsu | T. Motokura | S. Chiba | A. Yoshimi | Miwako Takahashi | K. Oshima
[1] K. Ohtomo,et al. FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Alavi,et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation , 2006, Bone Marrow Transplantation.
[5] J. Vose,et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Mackinnon,et al. Use of 18F‐FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions , 2005, British journal of haematology.
[7] K. Kawa,et al. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. , 2004, Blood.
[8] W. Au,et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] E. Vellenga,et al. Predictive value of early 18F‐fluoro‐deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma , 2003, British journal of haematology.
[10] M. Phelps,et al. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. , 2003, Chest.
[11] P. Dupont,et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. , 2003, Blood.
[12] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[13] U. Jaeger,et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation , 2002, Leukemia.
[14] B Beuthien-Baumann,et al. Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[15] S. Stewart,et al. T‐cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement , 2001, British journal of haematology.
[16] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Cahn,et al. Allogeneic bone marrow transplantation in aggressive non‐Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database , 1999 .
[18] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[20] U. Cremerius,et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. , 1998, Nuclear medicine communications.
[21] J Kotzerke,et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Armitage,et al. Allogeneic bone marrow transplantation for low-grade lymphoma. , 1998, Blood.
[23] C. E. al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.
[24] P. Gaulard,et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de Moelle. , 1999, British journal of haematology.
[25] M. Tomonaga,et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature , 1999, Bone Marrow Transplantation.
[26] D. Bumann,et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] M. Kaminski,et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.